These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26617181)

  • 41. Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer's disease using bedside cognitive assessments.
    Clarke A; Ashe C; Jenkinson J; Rowe O; A D N I ; Hyland P; Commins S
    J Clin Exp Neuropsychol; 2022 Dec; 44(10):703-712. PubMed ID: 36803664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Shortening the Alzheimer's disease assessment scale cognitive subscale.
    Levine SZ; Goldberg Y; Rotstein A; Samara M; Yoshida K; Cipriani A; Iwatsubo T; Leucht S; Furukawa TA
    Eur Psychiatry; 2024 Feb; 67(1):e19. PubMed ID: 38389390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What is the clinically relevant change on the ADAS-Cog?
    Schrag A; Schott JM;
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):171-3. PubMed ID: 22019547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Llano DA; Laforet G; Devanarayan V;
    Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimal clinically important difference in Alzheimer's disease: Rapid review.
    Muir RT; Hill MD; Black SE; Smith EE
    Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
    Schneider LS; Kennedy RE; Wang G; Cutter GR
    Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.
    Weyer G; Erzigkeit H; Kanowski S; Ihl R; Hadler D
    Int Psychogeriatr; 1997 Jun; 9(2):123-38. PubMed ID: 9309486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.
    Scheltens NME; Tijms BM; Heymans MW; Rabinovici GD; Cohn-Sheehy BI; Miller BL; Kramer JH; Wolfsgruber S; Wagner M; Kornhuber J; Peters O; Scheltens P; van der Flier WM;
    J Alzheimers Dis; 2018; 65(3):1029-1039. PubMed ID: 30103316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID).
    Verhey FR; Houx P; Van Lang N; Huppert F; Stoppe G; Saerens J; Böhm P; De Vreese L; Nordlund A; DeDeyn PP; Neri M; Peña-Casanova J; Wallin A; Bollen E; Middelkoop H; Nargeot MC; Puel M; Fleischmann UM; Jolles J
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):41-50. PubMed ID: 14716698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.
    Benoit JS; Chan W; Piller L; Doody R
    Am J Alzheimers Dis Other Demen; 2020; 35():1533317520918719. PubMed ID: 32573256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Executive function impairment in community elderly subjects with questionable dementia.
    Lam LC; Lui VW; Chiu HF; Chan SS; Tam CW
    Dement Geriatr Cogn Disord; 2005; 19(2-3):86-90. PubMed ID: 15572877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease.
    Ritchie CW; Khandker RK; Pike J; Black CM; Jones E; Ambegaonkar BM
    J Alzheimers Dis; 2018; 64(3):899-910. PubMed ID: 29966202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
    Pavlik VN; Chan W; Darby E
    J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study.
    Sjögren MJ; Hellström PT; Jonsson MA; Runnerstam M; Silander HC; Ben-Menachem E
    J Clin Psychiatry; 2002 Nov; 63(11):972-80. PubMed ID: 12444809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study.
    Garbóczy S; Magócs É; Szőllősi GJ; Harsányi S; Égerházi A; Kolozsvári LR
    BMC Psychiatry; 2020 Dec; 20(1):571. PubMed ID: 33256672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.